X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (221) 221
Publication (24) 24
Book / eBook (3) 3
Dissertation (3) 3
Book Chapter (2) 2
Book Review (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (94) 94
index medicus (72) 72
male (65) 65
oncology (60) 60
aged (41) 41
cancer (39) 39
middle aged (38) 38
care and treatment (36) 36
prostate cancer (31) 31
research (28) 28
chemotherapy (27) 27
adult (25) 25
female (25) 25
urology & nephrology (23) 23
treatment outcome (22) 22
metastasis (21) 21
prostatic neoplasms - drug therapy (21) 21
urology (20) 20
docetaxel (18) 18
aged, 80 and over (17) 17
analysis (17) 17
survival (17) 17
antineoplastic agents - therapeutic use (15) 15
article (15) 15
bladder cancer (15) 15
dermatology (15) 15
drug therapy (15) 15
health aspects (14) 14
neoplasm metastasis (14) 14
kidney neoplasms - pathology (13) 13
prognosis (13) 13
therapy (13) 13
diagnosis (12) 12
abiraterone acetate (11) 11
antineoplastic combined chemotherapy protocols - therapeutic use (11) 11
development and progression (11) 11
prostatic neoplasms - mortality (11) 11
prostatic neoplasms - pathology (11) 11
risk factors (11) 11
disease progression (10) 10
immunotherapy (10) 10
men (10) 10
animals (9) 9
carcinoma (9) 9
carcinoma, renal cell (9) 9
clinical trials (9) 9
disease-free survival (9) 9
immunology (9) 9
kaplan-meier estimate (9) 9
medicine & public health (9) 9
patients (9) 9
retrospective studies (9) 9
survival analysis (9) 9
antineoplastic agents - adverse effects (8) 8
double-blind (8) 8
double-blind method (8) 8
expression (8) 8
metastases (8) 8
mitoxantrone plus prednisone (8) 8
neoplasm staging (8) 8
patient outcomes (8) 8
prostatic neoplasms, castration-resistant - drug therapy (8) 8
tumors (8) 8
urinary bladder neoplasms - drug therapy (8) 8
urinary bladder neoplasms - pathology (8) 8
usage (8) 8
androgen antagonists - therapeutic use (7) 7
antineoplastic agents (7) 7
antineoplastic combined chemotherapy protocols - adverse effects (7) 7
cancer therapies (7) 7
carcinoma, renal cell - drug therapy (7) 7
enzalutamide (7) 7
kidney neoplasms - drug therapy (7) 7
lung-cancer (7) 7
melanoma (7) 7
mitoxantrone (7) 7
pharmacology & pharmacy (7) 7
radiotherapy (7) 7
renal cell carcinoma (7) 7
trial (7) 7
androgen-deprivation therapy (6) 6
antimitotic agents (6) 6
antineoplastic agents, hormonal - therapeutic use (6) 6
carcinoma, renal cell - pathology (6) 6
case studies (6) 6
cisplatin (6) 6
disease (6) 6
hematology, oncology and palliative medicine (6) 6
increased survival (6) 6
medical research (6) 6
medicine (6) 6
oncology, experimental (6) 6
pathology (6) 6
prednisone (6) 6
prostatic neoplasms, castration-resistant - pathology (6) 6
sorafenib (6) 6
urinary bladder neoplasms - therapy (6) 6
vascular endothelial growth factor (6) 6
allergology (5) 5
androgen antagonists - adverse effects (5) 5
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


ONCOLOGY (United States), ISSN 0890-9091, 11/2013, Volume 27, Issue 11, pp. 1158 - 1160
Journal Article
Oncology (Williston Park, N.Y.), ISSN 0890-9091, 12/2018, Volume 32, Issue 12, p. 607
Journal Article
Journal of Urology, ISSN 0022-5347, 2013, Volume 189, Issue 1, p. S43
Journal Article
Journal of Urology, ISSN 0022-5347, 01/2013, Volume 189, Issue 1S
Journal Article
Journal of Urology, The, ISSN 0022-5347, 2013, Volume 189, Issue 1, pp. S43 - S43
Journal Article
The Journal of Urology, ISSN 0022-5347, 01/2013, Volume 189, Issue 1, pp. S43 - S43
Journal Article
JNCCN Journal of the National Comprehensive Cancer Network, ISSN 1540-1405, 05/2018, Volume 16, Issue 5S, pp. 636 - 638
Urothelial carcinoma is the predominant histologic type of bladder cancer. After 30 years of minimal progress in the treatment of advanced-stage disease,... 
MULTICENTER | PEMBROLIZUMAB | ONCOLOGY | CISPLATIN-INELIGIBLE PATIENTS | IMMUNOTHERAPY | RESISTANCE | PHASE-2 | ATEZOLIZUMAB | FUTURE | SINGLE-ARM | CANCER
Journal Article
Lancet Oncology, ISSN 1470-2045, 2015, Volume 16, Issue 2, pp. 152 - 160
Journal Article
ONCOLOGY (United States), ISSN 0890-9091, 2018, Volume 32, Issue 12, pp. 607 - 609
Journal Article
Journal of the National Comprehensive Cancer Network : JNCCN, 05/2019, Volume 17, Issue 5.5, p. 591
The treatment landscape of bladder cancer has changed rapidly over the past several years. The 2019 version of the NCCN Guidelines has integrated changes to... 
Journal Article
ONCOLOGY (United States), ISSN 0890-9091, 12/2015, Volume 29, Issue 12, pp. 956 - 962
Traditionally, androgen deprivation therapy (ADT) has been the standard initial treatment for metastatic hormone-sensitive prostate cancer (mHSPC), with... 
TRIAL | MITOXANTRONE PLUS PREDNISONE | ANDROGEN-DEPRIVATION | ONCOLOGY | PHASE-I/II | DOUBLE-BLIND | ABIRATERONE ACETATE | OPEN-LABEL | INCREASED SURVIVAL | DOCETAXEL | RADIATION-THERAPY | Prostatic Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Clinical Trials as Topic | Humans | Prostatic Neoplasms - drug therapy
Journal Article
Journal of Urology, ISSN 0022-5347, 05/2009, Volume 181, Issue 5, p. 2007
Journal Article
The Journal of Urology, ISSN 0022-5347, 05/2009, Volume 181, Issue 5, pp. 2007 - 2007
Journal Article
Journal of Urology, ISSN 0022-5347, 05/2009, Volume 181, Issue 5, pp. 2007 - 2007
Journal Article
The Journal of Urology, ISSN 0022-5347, 05/2009, Volume 181, Issue 5
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2013, Volume 368, Issue 2, pp. 138 - 148
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 01/2013, Volume 19, Issue 1, pp. 148 - 157
Journal Article
ONCOLOGY (United States), ISSN 0890-9091, 11/2014, Volume 28, Issue 11, p. 1
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2011, Volume 364, Issue 21, pp. 1995 - 2005
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.